Hprt mutations and karyotype abnormalities in T-cell clones from healthy subjects and melphalan-treated ovarian carcinoma patients

Mutat Res. 1989 Feb;210(2):353-8. doi: 10.1016/0027-5107(89)90097-3.

Abstract

In vivo mutations at the locus for hypoxanthine phosphoribosyl transferase (hprt) were studied in 6-thioguanine (TG)-resistant T-lymphocyte clones from healthy male and female subjects and ovarian carcinoma patients treated with melphalan. Southern blot analysis of 108 clones showed alterations in 14% (4/29) of the clones from healthy males, 4.3% (2/47) of the clones from healthy females and 3.1% (1/32) of the clones from melphalan-treated patients. 2 of the 7 abnormal clones had a total deletion of the hprt gene; the others had partial deletions. Karyotype analysis of 82 clones revealed 1 clonal abnormality in 29 mutant clones from healthy males (3.6%). Loss or structural aberration of 1 X-chromosome occurred in 6% of the clones from healthy females. The frequency of karyotypic abnormalities (excluding those affecting one of the X-chromosomes) was significantly higher in clones from patients (37%) as compared to healthy females (5.9%). No aberration was found to affect the hprt locus at Xq27 in any of the 82 clones studied.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Blotting, Southern
  • Carcinoma / drug therapy
  • Chromosome Aberrations / pathology*
  • Chromosome Disorders
  • Clone Cells
  • Female
  • Humans
  • Hypoxanthine Phosphoribosyltransferase / genetics*
  • Karyotyping
  • Melphalan / adverse effects
  • Mutation*
  • Ovarian Neoplasms / drug therapy
  • T-Lymphocytes / enzymology
  • T-Lymphocytes / physiology*
  • T-Lymphocytes / ultrastructure

Substances

  • Hypoxanthine Phosphoribosyltransferase
  • Melphalan